The Effect of a Loading Dose Regimen in the Switch to Brolucizumab for Patients with Aflibercept-Resistant nAMD

CONCLUSION: Switching to brolucizumab from aflibercept for eyes with nAMD with resistance to bimonthly injections of aflibercept is a valuable treatment option with and without the loading regimen. This trial is registered with UMIN000023676.PMID:38322501 | PMC:PMC10846919 | DOI:10.1155/2024/3673930

Source: Journal of Ophthalmology - February 7, 2024 Category: Opthalmology Authors: Hiroyuki Kamao Erika Mitsui Yuto Date Katsutoshi Goto Kenichi Mizukawa Atsushi Miki Source Type: research